Nothing brings out the passionate debate like the controversy of PSA. It is well-known that there is no consensus evidence showing a mortality benefit to obtaining a screening PSA. An upcoming trial is supposed to more definitively answer the question, but recruiting patients may be difficult:
Many are awaiting the results of a multiyear trial by the National Cancer Institute and other medical organizations called the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. PSA experts at the conference pointed out, however, that enrolling patients in a randomized controlled trial where some patients forego screening will be difficult because of the widespread acceptance of PSA screening.
